Nature, Published online: 05 November 2025; doi:10.1038/s41586-025-09721-5

The combination of computational design, laboratory-based screening and biophysical validation enables the de novo generation of variable heavy-chain antibody fragments and antibodies that precisely target chosen disease-related molecules.

From Nature via this RSS feed